<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809105</url>
  </required_header>
  <id_info>
    <org_study_id>0456-CL-1031</org_study_id>
    <nct_id>NCT02809105</nct_id>
  </id_info>
  <brief_title>A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation</brief_title>
  <official_title>Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Open-label, Non-comparative Long-term Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to verify the efficacy and investigate the safety of the study
      drug when ASP0456 is administered orally for 4 weeks and 52 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts. In Part I, ASP0456 or placebo will be administered orally
      in a blind manner. In Part II, the long-term safety and efficacy of ASP0456 will be evaluated
      in patients who have participated in the study and completed the Part I.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2016</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">November 14, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in weekly mean SBM frequency during one week of administration (Part I)</measure>
    <time_frame>Baseline and Week 1</time_frame>
    <description>SBM: Spontaneous bowel movement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean SBM frequency</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly responder rate of SBM</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SBM within 24 hours after the start of the initial administration</measure>
    <time_frame>Up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first SBM</measure>
    <time_frame>Up to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean CSBM frequency</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
    <description>CSBM: SBM witout a sensation of incomplete evacuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly responder rate of CSBM</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with CSBM within 24 hours after the start of the initial administration</measure>
    <time_frame>Up to 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean stool form score</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean abdominal bloating severity score</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean abdominal pain/discomfort severity score</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean straining severity score</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly responder rate of global assesment of relief of CC symptoms</measure>
    <time_frame>Up to Week 56</time_frame>
    <description>CC: chronic constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly responder rate of abnormal bowel habits improvement in CC</measure>
    <time_frame>Up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly responder rate of abdominal symptoms relief of CC</measure>
    <time_frame>Up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IBS-QOL-J score</measure>
    <time_frame>Baseline and up to Week 56</time_frame>
    <description>IBS-QOL-J: Japanese version of Irritable Bowel Syndrome Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence of adverse events</measure>
    <time_frame>Up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Vital signs and/or adverse events during treatment period</measure>
    <time_frame>Up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Laboratory values and/or adverse events during treatment period</measure>
    <time_frame>Up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by body weight</measure>
    <time_frame>Up to Week 56</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Chronic Constipation</condition>
  <arm_group>
    <arm_group_label>Part I ASP0456</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0456 will be administered orally for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II ASP0456</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP0456 will be administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linaclotide</intervention_name>
    <description>Oral administration once daily</description>
    <arm_group_label>Part II ASP0456</arm_group_label>
    <arm_group_label>Part I ASP0456</arm_group_label>
    <other_name>ASP0456</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration once daily</description>
    <arm_group_label>Part I Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SBM frequency for &lt; 3 times/week, since ≥ 6 months prior to preliminary
             enrollment

          -  Patients with one or more related symptoms for ≥ 6 months prior to preliminary
             enrollment

          -  Patients at whom loose (mushy) or watery stools are rarely present without the use of
             laxatives for ≥ 6 months prior to preliminary enrollment

          -  Patients who underwent pancolonoscopy or contrast enema after development of the CC
             symptoms and within 5 years prior to preliminary enrollment, and in whom no organic
             change was observed which dose not influence on CC symptoms

          -  Female patients must be either:

        Be of non-childbearing potential:

          -  Post-menopausal at the preliminary enrollment, or documented surgically sterile Or, if
             of childbearing potential,

          -  Agree not to try to become pregnant during the study and for 28 days after the final
             study drug administration

          -  And have a negative urine pregnancy test at screening

          -  And, if heterosexually active, agree to consistently use two forms of highly effective
             birth control throughout the study period and for 28 days after the final study drug
             administration

               -  Female patients must agree not to breastfeed throughout the study period and for
                  28 days after the final study drug administration

               -  Female patients must not donate ova starting throughout the study period and for
                  28 days after the final study drug administration

               -  Male subject and their female spouse/partners who are of childbearing potential
                  must be using two forms of highly effective form of birth control starting at
                  Screening and continue throughout the study period, and for 28 days after the
                  final study drug administration

               -  Male subject must not donate sperm starting at Screening and throughout the study
                  period and, for 28 days after the final study drug administration

        Exclusion Criteria:

          -  Patients who have met the Rome III diagnostic criteria for IBS; with recurrent
             abdominal pain or discomfort for ≥ 3 days/month in the last 3 months prior to
             preliminary enrollment, associated with ≥ 2 of the 3 characteristics described below
             and with the symptoms (IBS symptoms) described above for ≥ 6 months prior to
             preliminary enrollment

               1. Improvement with defecation

               2. Onset associated with a change in frequency of stool

               3. Onset associated with a change in form (appearance) of stool

          -  Patients with a history of surgical resection of the stomach, gallbladder, small
             intestine, or large intestine

          -  Patients with a history or current evidence of inflammatory bowel disease or ischemic
             colitis

          -  Patients with concurrent infectious enteritis, hyperthyroidism or hypothyroidism,
             constipation due to anorectal dysfunction, drug-induced constipation, constipation due
             to other organic diseases or active peptic ulcer

          -  Patients with apparent mechanical obstruction

          -  Patients with megacolon or megarectum

          -  For female patients, patients with concurrent endometriosis or adenomyosis

          -  Patients who are considered to have severe depression or a severe anxiety disorder
             that can affect the efficacy evaluation of the study drug

          -  Patients with a history of abuse of drugs or alcohol, or current abuse of drugs or
             alcohol

          -  Patients who used/underwent or are scheduled to use/undergo prohibited concomitant
             drugs or therapies, or in whom prohibited examinations were conducted or are scheduled
             to be conducted 3 days prior to the start of the bowel habit observation period

          -  Patients with a history or current evidence of malignant tumors

          -  Patients with concurrent serious cardiovascular diseases, respiratory diseases, renal
             diseases, hepatic diseases, gastrointestinal disorders, blood diseases, or
             neurological/psychiatric diseases

          -  Patients with a history of drug allergies

          -  Patients who have participated in the clinical trial of ASP0456 or with a history of
             ASP0456 administration

          -  Patients who have participated or are participating in another clinical trial or
             post-marketing clinical study of other ethical drugs or medical devices within 12
             weeks prior to obtaining informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00029</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00030</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00021</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00022</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00023</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00024</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00040</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00037</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00038</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00039</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00017</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00018</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00019</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00020</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00031</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00032</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00033</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00034</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00035</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00036</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00025</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00026</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00027</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00028</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00007</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00008</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00009</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00010</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00011</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00012</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00013</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00014</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00015</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic constipation</keyword>
  <keyword>Linaclotide</keyword>
  <keyword>ASP0456</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

